BioSpace News Archive

Despite the COVID-19 pandemic, the U.S. Food and Drug Administration has managed to stay fairly on track in terms of evaluating new drug and supplemental new drug applications. Here’s a look at what’s on the schedule for the next two weeks.

The culling of one-fourth of its employees is expected to save the company approximately $125 million through the end of 2021.

Quantzig, a global data analytics and advisory firm, that delivers actionable analytics solutions to resolve complex business problems has announced the completion of its recent engagement- Pharmacovigilance: Improving Drug Development Amid The Covid-19 Crisis

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and Mount Sinai Health System (" Mount Sinai ") have agreed to join forces in the investigation and development of an antibody cocktail (COVI-SHIELD™) to potentially treat COVID-19.

New data provides evidence of adaptive cellular (CD8+ cells) and balanced (Th1/Th2) immune responses STARR™ mRNA elicits anti-spike protein antibodies (IgG), higher than conventional mRNA at all doses SAN DIEGO, May 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, tod

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Friday, May 15, 2020 at 10:00 a.m. EDT.

Therap Services, the long-standing leader in offering innovative electronic solutions for organizations supporting people in long term care supports, is happy to offer a plan designed for individuals and families to keep track of their personal information, appointments, medical support needs, daily activities, and more.

HJB, today announces that its partner Mabspace Biosciences has received Investigational New Drug (IND) clearance from both the U.S. Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA), for a humanized Claudin18.2 monoclonal antibody program.

New 36-week data showed higher investigational doses of Trulicity (3 mg and 4.5 mg) were well-tolerated and led to A1C reductions up to 1.9 percent and weight reductions up to 10.4 pounds in people with type 2 diabetes.

Perrigo Company plc announced that President and CEO Murray S. Kessler will host a fireside chat at the RBC Capital Markets Global Healthcare Conference at 11:30 AM EDT on Wednesday, May 20, 2020.